Fenbendazole, a deworming drug sold over the counter for dogs, cattle, and other animals, has shown genuine anticancer activity in laboratory dishes and in mice, but there is no clinical trial evidence proving it works against cancer in humans. The gap between a promising lab finding and a proven treatment is enormous, and fenbendazole sits firmly on the lab side of that gap. A handful of case reports describe cancer patients who took fenbendazole alongside other therapies and experienced remission, while other reports document serious liver injury from the drug. The story is more complicated than either the hopeful social media posts or the dismissive medical establishment responses suggest.
How a Dog Dewormer Became a Cancer Trend
The fenbendazole-cancer phenomenon exploded in 2019 when an Oklahoma man named Joe Tippens publicly claimed the drug helped cure his terminal lung cancer. His story spread across YouTube, Facebook groups, and blogs, eventually gaining traction in South Korea, where fenbendazole use among cancer patients became so widespread that researchers began studying the trend itself. A cross-sectional survey of South Korean cancer patients who had tried anthelmintic therapy found that roughly four in five believed the treatment was effective. Over half said they felt it improved their physical condition, and about a third perceived that it reduced the spread of their cancer.1PLoS ONE. Experience with and perceptions of non-prescription anthelmintics for cancer treatments among cancer patients in South Korea: A cross-sectional survey
These are perceptions, not clinical measurements. No imaging or lab data confirmed whether the perceived improvements were real. But the survey illustrates something important about why fenbendazole gained such momentum: cancer patients, particularly those with advanced disease, are desperate for options, and anecdotal success stories are emotionally compelling in a way that statistical uncertainty never will be. The drug is cheap, available without a prescription at farm supply stores, and feels like a low-stakes experiment. That combination made it spread faster than the science could keep up with.
What Fenbendazole Does in Lab Experiments
Fenbendazole belongs to the benzimidazole family of drugs, which kill parasitic worms by binding to a protein called tubulin. Tubulin forms the structural scaffolding inside cells, and when it gets disrupted, cells cannot divide properly. Cancer cells divide rapidly, so anything that interferes with their internal scaffolding has at least theoretical anticancer potential. In fact, some established chemotherapy drugs work by a similar mechanism.
Lab studies have confirmed that fenbendazole does disrupt tubulin in human cancer cells, though its effect is milder than that of dedicated anticancer drugs targeting the same protein. In one widely cited study using human non-small-cell lung cancer cells, fenbendazole caused modest tubulin disruption and triggered cancer cell death through several pathways simultaneously. Compared to colchicine and nocodazole, which are well-known microtubule-disrupting agents, fenbendazole’s tubulin-destabilizing activity was relatively mild, but it still killed cancer cells effectively in the dish.2PubMed Central. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways Separate work on canine brain tumor cells confirmed similar tubulin disruption after fenbendazole treatment.3PubMed. In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells
The fact that fenbendazole hits multiple pathways, not just tubulin, is part of what makes it interesting to researchers. But “interesting in a petri dish” is a very early stage. Thousands of compounds kill cancer cells in lab experiments and then fail in living organisms because the drug cannot reach the tumor at a high enough concentration, gets broken down too quickly, or causes unacceptable side effects.
Animal Studies and the Vitamin Wrinkle
One of the most frequently cited animal studies came about by accident. Researchers at Johns Hopkins were using mice implanted with human lymphoma tumors for an unrelated experiment when they noticed something odd. Mice that had been given fenbendazole as a routine deworming agent, combined with supplementary vitamins (including vitamins A, D, E, and B complex), had tumors that were significantly smaller and slower to develop than those in untreated control mice. Fenbendazole alone did not produce a statistically significant reduction in tumor growth, and vitamins alone did not either. Only the combination showed the effect.4PubMed Central. Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins
This finding is both tantalizing and frustrating. It suggests that fenbendazole might need a co-factor to work, which adds complexity. And it was a single study using one tumor type in mice, not a systematic dose-finding trial. The “Joe Tippens protocol” that circulates online, which typically includes fenbendazole plus vitamin E and curcumin, seems partly inspired by this study, though the specific regimen was never formally tested in a controlled setting.
More recent preclinical work has explored fenbendazole against ovarian cancer in mouse models. Researchers developed nanoparticle formulations to improve the drug’s solubility and found that these formulations significantly reduced tumor weight in mice, including in drug-resistant tumor models and patient-derived xenograft models.5PubMed Central. Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer This points to both the drug’s potential and a core problem that needs solving before it could work in humans.
The Bioavailability Problem
Fenbendazole was designed to kill gut parasites in animals. It does not need to be absorbed well into the bloodstream to do that job — it mostly stays in the gastrointestinal tract, which is exactly where the worms are. But to fight cancer, a drug needs to reach tumors throughout the body at concentrations high enough to kill cancer cells.
Animal pharmacokinetic studies paint a consistent picture: fenbendazole’s oral bioavailability is low. In pigs, only about 27% of an oral dose reached the bloodstream, and peak blood levels were extremely low.6PubMed. Pharmacokinetics of fenbendazole following intravenous and oral administration to pigs In alpacas, systemic bioavailability averaged just 16%, with wide variation between individual animals.7PubMed Central. Plasma concentrations of fenbendazole (FBZ) and oxfendazole in alpacas (Lama pacos) after single intravenous and oral dosing of FBZ In dogs, taking the drug with food significantly increased absorption compared to taking it on an empty stomach, but the absolute levels remained modest.8PubMed. Oral absorption and bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food
No formal pharmacokinetic studies of fenbendazole have been published in humans. We do not actually know what blood levels people achieve when they take the typical self-prescribed doses, or whether those levels come anywhere close to the concentrations that killed cancer cells in laboratory experiments. The concentrations used in cell-culture studies are often much higher than what the body can realistically sustain after an oral dose of a poorly absorbed drug. This is the central unsolved question of the fenbendazole-cancer hypothesis, and until someone runs those human pharmacokinetic studies, the lab data remain untethered from clinical reality.
How the Body Processes Fenbendazole
In the liver, fenbendazole is primarily broken down by two enzymes called CYP2C19 and CYP2J2.9PubMed Central. CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems This matters for two practical reasons. First, CYP2C19 activity varies widely between individuals due to genetic differences. Some people are “poor metabolizers” who break down the drug slowly, which could lead to higher-than-expected blood levels and potentially more side effects. Others are “ultra-rapid metabolizers” who clear it so quickly that the drug might never reach meaningful concentrations. Second, many common medications and supplements affect these same enzymes. Someone taking proton pump inhibitors, certain antidepressants, or antifungal drugs could be altering how their body handles fenbendazole in unpredictable ways.
The drug’s main metabolite, oxfendazole, accounts for a large share of what actually circulates in the blood after a dose. Some researchers believe oxfendazole may have its own anticancer activity, but this has been studied even less than fenbendazole itself. The whole metabolic picture in humans remains sketchy.
Case Reports in Humans
No randomized controlled trial of fenbendazole for cancer exists. What the medical literature contains, as of mid-2025, is a small number of case reports — individual patient stories documented by physicians. A recent case series described three patients with advanced cancers (breast, prostate, and melanoma) who added fenbendazole to their treatment regimens. These patients were not receiving chemotherapy but were using other therapies. Two achieved complete remission, and one achieved near-complete remission, with follow-up periods ranging from 11 months to nearly three years. None reported adverse effects from the drug.10PubMed Central. Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients
These results sound dramatic, but case reports sit at the bottom of the evidence hierarchy for good reason. The patients were taking other treatments simultaneously, making it impossible to attribute the remission to fenbendazole. Spontaneous remissions, though rare, do occur. Publication bias also plays a role: patients who took fenbendazole and got worse are far less likely to end up in a published case report. Three favorable outcomes with no control group tell us that this is worth studying in a rigorous trial, not that the drug works.
Safety Risks That Do Not Make the Social Media Posts
Fenbendazole is extremely safe in animals at standard deworming doses, which is one reason people assume it is safe for human use. But humans are not dogs, doses being discussed in cancer protocols are often higher than deworming doses, and “safe for short-term parasite treatment” is different from “safe when taken daily for months.”
The most concerning documented risk is liver injury. A case report from South Korea described a woman with non-small-cell lung cancer who developed markedly elevated liver enzymes after self-administering fenbendazole. She had been taking the drug based on social media advice. Her liver function returned to normal after stopping fenbendazole, but her cancer progressed during the interruption of her immunotherapy, and the causality assessment indicated a probable adverse drug reaction.11PubMed Central. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information
A more severe case was reported later: a patient developed confirmed severe drug-induced liver injury from fenbendazole, with dangerously elevated bilirubin and impaired blood clotting. A biopsy confirmed the liver damage, and the formal causality scoring indicated a high probability that fenbendazole was responsible. The patient’s liver function recovered after stopping the drug.12PubMed Central. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole These are not common outcomes — plenty of people take fenbendazole without obvious liver problems — but they are serious enough to warrant regular liver function monitoring for anyone taking the drug, which most self-treating patients are not doing.
There is also a subtler safety issue. Fenbendazole is not manufactured or quality-controlled for human consumption. The veterinary formulations people buy at feed stores may contain inactive ingredients or fillers that were never tested for human safety. Dosing is guesswork, since no human dose has been established for any indication.
The Bigger Risk of Replacing or Delaying Proven Treatment
The most dangerous aspect of the fenbendazole trend may not be the drug itself but what patients do with their conventional treatment while pursuing it. Research consistently shows that cancer patients who use alternative therapies are more likely to refuse or delay surgery, chemotherapy, and radiation. A study of patients with curable cancers found that those using complementary medicine had substantially higher refusal rates for surgery, chemotherapy, radiotherapy, and hormone therapy compared to patients who did not use complementary approaches.13PubMed Central. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers A separate analysis found that patients choosing alternative medicine over conventional treatment had roughly two and a half times the risk of death overall, with breast cancer patients facing over five times the risk.14JNCI: Journal of the National Cancer Institute. Use of Alternative Medicine for Cancer and Its Impact on Survival
A systematic review and meta-analysis confirmed this pattern more broadly, finding that use of complementary and alternative medicine was associated with roughly double the odds of both diagnostic delay and treatment delay.15Nowotwory. Journal of Oncology. Complementary and alternative medicine and the risk of delayed diagnosis and treatment for cancer patients: a systematic review and meta-analysis The critical nuance from the JAMA Oncology study is revealing: when the analysis accounted for treatment refusal and delay, complementary medicine use itself was no longer significantly associated with worse survival. In other words, the danger was not the supplements or alternative therapies per se — it was the decision to skip or postpone proven treatments.16PubMed Central. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers
For anyone considering fenbendazole, the evidence-based position is straightforward: there is no justification for using it instead of conventional cancer treatment. Using it alongside standard therapy, with your oncologist’s knowledge, is a different conversation — still unproven, still carrying liver risk, but not the same as gambling your life on a veterinary dewormer.
Mebendazole and the Benzimidazole Family
Fenbendazole is not the only benzimidazole attracting cancer research interest. Its close relatives, mebendazole and albendazole, have been studied more extensively, including in human clinical trials. A review of the evidence found that both albendazole and mebendazole showed activity against liver, lung, ovarian, prostate, colorectal, and breast cancers in lab and animal studies. A few case reports in human patients showed promising results. Mebendazole has emerged as the preferred candidate for clinical development because albendazole can cause significant bone-marrow suppression at the high doses needed for prolonged treatment.17PubMed Central. Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Mebendazole has an advantage over fenbendazole in one crucial respect: it is already approved for human use as a prescription antiparasitic in many countries. This means its safety profile in humans is better characterized, its dosing is better understood, and clinical trials are easier to conduct because the regulatory pathway is clearer. Several clinical trials of mebendazole for various cancers have been registered or completed, though results remain preliminary. If the benzimidazole-cancer hypothesis eventually pans out, mebendazole is more likely to be the version that gets formally tested and potentially approved, simply because the path from veterinary dewormer to human medicine is far longer and more uncertain for fenbendazole.
Nanoparticle Formulations and the Solubility Challenge
One active area of research aims to solve fenbendazole’s poor absorption by packaging it in engineered nanoparticles. The ovarian cancer study mentioned earlier used a polymer-based nanoparticle system to make fenbendazole water-soluble and injectable. The nanoparticle formulation reduced tumor weight in mice significantly more than fenbendazole alone, including in tumors resistant to standard chemotherapy drugs.18PubMed Central. Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer This is a proof of concept, not a treatment ready for patients. But it addresses the bioavailability problem head-on and suggests that if fenbendazole has genuine anticancer effects in the body, better drug delivery could unlock them.
These formulations are years away from human testing, assuming they proceed at all. For the people buying veterinary fenbendazole powder at feed stores today, nanoparticle delivery is irrelevant — they are taking the raw drug in its least absorbable form, making the gap between what happens in a petri dish and what happens in their body even wider.
What Would It Take to Know for Sure
The honest answer is that the fenbendazole question could be resolved relatively quickly if someone funded the right studies. The first step would be a human pharmacokinetic study: give healthy volunteers or cancer patients oral fenbendazole at various doses, measure blood and tissue levels, and determine whether those levels come anywhere near the concentrations that kill cancer cells in the lab. If they do, a phase I/II clinical trial would test whether the drug shrinks tumors or slows progression in a defined patient population, with proper controls. These studies would not be especially expensive by clinical trial standards, and the drug is off-patent, which removes some intellectual-property barriers.
The reason this has not happened is a mix of economics and incentives. No pharmaceutical company can patent fenbendazole, so there is little financial motivation to fund a large trial. Academic researchers have published the preclinical work, but moving from mouse studies to human trials requires substantial funding and regulatory effort. Meanwhile, patients are running their own uncontrolled experiment in the real world, generating anecdotes but not data. The case series of three patients represents the closest thing to formal human documentation so far, and three patients with no control group and concurrent treatments is a very thin thread to hang hope on.
Some researchers have argued that the benzimidazole family deserves the kind of systematic repurposing effort that has been given to drugs like metformin or aspirin for cancer prevention. The preclinical signal is real, the drugs are cheap and widely available, and the mechanisms are plausible. Whether the scientific establishment and funding agencies will take that argument seriously enough to run the trials remains an open question — one that online communities and medical institutions seem to be answering in very different ways.